About
Technology
Issues
FAQ
Links
Official Page
Efficacy and Tolerability of 5-Year Adjuvant Imatinib Treatment for Patients With Resected Intermediate- or High-Risk Primary Gastrointestinal Stromal Tumor
Distribution of the number of citations over years.
site/software ©
exaly
; All materials licenced under
CC by-SA
.